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ABSTRACT: The ongoing COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has
resulted in more than 28,000,000 infections and 900,000 deaths worldwide to date. Antibody development efforts mainly revolve
around the extensively glycosylated SARS-CoV-2 spike (S) protein, which mediates host cell entry by binding to the angiotensin-
converting enzyme 2 (ACE2). Similar to many other viral fusion proteins, the SARS-CoV-2 spike utilizes a glycan shield to thwart
the host immune response. Here, we built a full-length model of the glycosylated SARS-CoV-2 S protein, both in the open and
closed states, augmenting the available structural and biological data. Multiple microsecond-long, all-atom molecular dynamics
simulations were used to provide an atomistic perspective on the roles of glycans and on the protein structure and dynamics. We
reveal an essential structural role of N-glycans at sites N165 and N234 in modulating the conformational dynamics of the spike’s
receptor binding domain (RBD), which is responsible for ACE2 recognition. This finding is corroborated by biolayer interferometry
experiments, which show that deletion of these glycans through N165A and N234A mutations significantly reduces binding to ACE2
as a result of the RBD conformational shift toward the “down” state. Additionally, end-to-end accessibility analyses outline a
complete overview of the vulnerabilities of the glycan shield of the SARS-CoV-2 S protein, which may be exploited in the therapeutic
efforts targeting this molecular machine. Overall, this work presents hitherto unseen functional and structural insights into the SARS-
CoV-2 S protein and its glycan coat, providing a strategy to control the conformational plasticity of the RBD that could be harnessed
for vaccine development.
■ INTRODUCTION
COVID-19 is an infectious respiratory disease that started in
Wuhan, China, near the end of 2019 and has now spread
worldwide as a global pandemic.1 This is not the first time that
a coronavirus has posed a threat to human health. Severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) is the
pathogen that causes COVID-19 and belongs to the same
family of viruses, Coronaviridae, as SARS and Middle East
respiratory syndrome (MERS) related coronaviruses, which
have resulted in previous epidemics.2−4 Owing to the lack of
immunity, COVID-19 has already caused a catastrophic loss of
human life worldwide5 as well as significant economic
damage.6
Coronaviruses, including SARS-CoV-2, are lipid-enveloped
positive-sense RNA viruses. Together with the host-derived
membrane, a set of structural proteins provides an organiza-
tional scaffold that wraps and contains the viral RNA. Among
them, the most critical is the spike, or S, protein, which is
conserved to varying degrees across the Coronaviridae family
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and plays a key role in the virus’ initial attachment and fusion
with the host cell. The S protein is a class I fusion protein,
synthesized as a single 1273 amino acid polypeptide chain,
which associates as a trimer. Each monomer is made of two
subunits, S1 and S2, and can be divided into three main
topological domains, namely the head, stalk, and cytoplasmic
tail (CT) (Figure 1A). One particularly interesting feature of
the SARS-CoV-2 S protein is its adoption of a novel furin
cleavage site between S1 and S2 (S1/S2), likely cleaved by the
TMPRSS2 protease7 and believed to prime the spike for
infection.8,9 A second proteolytic cleavage at site S2′ releases
the fusion peptide (FP), which penetrates the host cell
membrane, preparing it for fusion.10 A number of recently
published structural studies have provided an atomic or a near-
atomic understanding of the head portion of the SARS-CoV-2
spike, which comprises multiple domains (Figures 1A and
1B).11,12 The S1 subunit contains an N-terminal domain
(NTD) and the receptor binding domain (RBD), where the
receptor binding motif (RBM) is responsible for the
interaction with the angiotensin-converting enzyme 2
(ACE2) receptor to gain entry into the host.13 The S2 subunit
has been aptly described as “a metastable spring-loaded fusion
machine” because it plays a key role in integrating the viral and
host cell membranes.14 It contains the FP, the central helix
(CH), and the connecting domain (CD). Additional domains
within the S2 subunit that are not resolved in the prefusion
state via cryo-EM or X-ray experiments include the heptad
repeat 2 (HR2) and the transmembrane (TM) domains
forming the stalk and the CT (Figures 1A and 1B).
Another key structural feature of the S protein that eludes
detailed experimental structural characterization is its extensive
glycosylation, shown in Figure 1C. Protein glycosylation plays
a crucial role in viral pathogenesis,15−17 as demonstrated by the
characteristically thick N-glycan coating of the viral fusion
proteins.18−21 In the HIV-1 envelope spike (Env), for example,
the protein-accessible surface area is almost entirely covered in
N-glycans.20,22 These are so densely packed that they account
for more than half of the protein’s molecular weight.23 The
biological roles of the N-glycans expressed on the surface of
viral envelope glycoproteins are very diverse16 and are all
inextricably linked to their nature. Viral entry through
membrane fusion is initiated by envelope glycoproteins
through molecular recognition events involving cell surface
receptors, which are often mediated by specific N-glycan
epitopes.16,24−26 Moreover, a highly dense coating of non-
immunogenic or weakly immunogenic complex carbohydrates
on otherwise dangerously exposed viral proteins constitutes a
perfect camouflage (or shield) to evade the immune
system.16,18,19,27,28 To this end, the HIV-1 Env glycan shield,
which is largely structured by oligomannose (Man5−9) N-
glycans,18,20,27,29 has been shown to be quite effective in
allowing the virus to thwart the immune system;15,16 it has also
Figure 1. System overview. (A) Schematic of the full-length SARS-CoV-2 S protein primary structure colored by domain: N-terminal domain
(NTD, 16−291), receptor binding domain (RBD, 330−530), furin cleavage site (S1/S2), fusion peptide (FP, 817−834), central helix (CH, 987−
1034), connecting domain (CD, 1080−1135), heptad repeat 2 (HR2, 1163−1210) domain, transmembrane domain (TM, 1214−1234), and
cytoplasmic tail (CT, 1235−1273). Representative icons for N-glycans (blue and green) and O-glycan (yellow) are also depicted according to their
position in the sequence. (B) Assembly of the head, stalk, and CT domains into the full-length model of the S protein in the open state. (C)
Glycosylated and palmitoylated full-length model of the S protein in the open state embedded in a lipid bilayer mimicking the composition of the
endoplasmic reticulum-Golgi intermediate compartment. Protein is depicted with gray cartoons, where the RBD in the “up” state is highlighted
with a transparent cyan surface. N-/O-glycans are shown in Van der Waals representation, where GlcNAc is colored in blue, mannose in green,
fucose in red, galactose in yellow, and sialic acid in purple. Color code used for lipid tails (licorice presentation): POPC (pink), POPE (purple),
POPI (orange), POPS (red), cholesterol (yellow). P atoms of the lipid heads are shown with green spheres. Cholesterol’s O3 atoms are shown with
yellow spheres. (D) Magnified view of the S protein head glycosylation, where glycans are depicted using the Symbol Nomenclature for Glycans
(SNFG). (E) Magnified view of the S protein stalk glycosylation. (F) Magnified view of the S protein S-palmitoylation within CT.
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been found to be responsible for the virus’ interactions with
DC-SIGN C-type lectins.30 Contrary to HIV-1 Env, the
betacoronaviruses SARS and MERS S proteins are not shielded
as effectively.15 Furthermore, both SARS-CoV and SARS-CoV-
2 spikes present a rather different glycosylation pattern from
that of HIV-1 Env, with a large presence of complex N-glycans
relative to oligomannose type.11,15,31 More specifically, the
SARS-CoV-2 spike has 22 predicted N-glycosylation sites per
protomer,11,12 of which at least 17 have been found to be
occupied,11,31 plus at least two predicted O-glycosylation sites
(see Figures 1C−1E).31
In this work, we present multiple microsecond-long, all-
atom, explicitly solvated molecular dynamics (MD) simu-
lations of the full-length SARS-CoV-2 S glycoprotein
embedded in the viral membrane, with a complete
glycosylation profile consistent with glycomic data.11,31 The
simulations discussed here augment and extend the available
structural and biological data to provide an atomically detailed
perspective on the full-length SARS-CoV-2 S protein’s glycan
coat, structure, and dynamics. Beyond shielding, our work
reveals an essential structural role of N-glycans linked to N165
and N234 in modulating the conformational transitions of the
RBD. Deletion of these glycans in our simulations elicits a
destabilizing effect on the RBD “up” conformation. These
results are corroborated via biolayer interferometry experi-
ments showing a reduction of ACE2-binding, which underlies
an increase of the RBD “down” population. Moreover, our
simulations highlight how glycans camouflage the SARS-CoV-
2 S protein for thwarting the host immune response. A detailed
analysis of the S protein’s glycan shield discloses a lack of
vulnerabilities in the stalk, particularly for large molecules,
whereas the head region appears to be a more viable target.
Importantly, an in-depth overview of the RBM accessibility
indicates a remarkably different extent of glycan shield between
the “up” and “down” RBD conformations. Overall, this work
provides an atomic-level perspective on the SARS-CoV-2 S
protein, highlighting the importance of glycans not only as
shielding devices for immune evasion but also as essential
structural elements for virus infectivity. These insights lay the
foundations for a possible strategy to modulate the RBD
conformational plasticity and virus infectivity, which could be
harnessed in the development of therapeutics aimed at fighting
the pandemic threat.
■ RESULTS AND DISCUSSION
All-Atom MD Simulations of the Full-Length Model
of the SARS-CoV-2 S Protein in Open and Closed States.
In this work, we built a complete, full-length model of the
glycosylated SARS-CoV-2 S protein in both closed and open
states, hereafter referred to as “Closed” and “Open”,
respectively. Closed is based on the cryo-EM structure
6VXX, where all three RBDs are in a “down” conformation.12
Open is based on the cryo-EM structure 6VSB, where the RBD
within chain A (RBD-A) is in an “up” conformation.32 A
detailed view of chains A, B, and C and the RBD “up/down”
conformations as in Open/Closed is shown in Figure S1 of the
Supporting Information (SI). These models were built in three
steps, as fully described in the Materials and Methods section
in the SI: (i) the “head”, comprising S1/S2 subunits until
residue 1140 and based on the above-mentioned experimental
coordinates;12,32 (ii) the “stalk” (residues 1141−1234),
comprising HR2 and TM domains and constructed through
homology modeling using MODELLER;33 and (iii) the CT
(residues 1235−1273) built using I-TASSER (Figures 1A).34
The modeled constructs (see Figure 1B for Open) were fully
glycosylated at N-/O-glycosylation sites11,31 (Figures 1C−1E)
and further refined with cysteine palmitoylation within the CT
(Figure 1F).35,36 An asymmetric (i.e., not specular across
monomers) site-specific glycoprofile totaling 70 glycans (22 ×
3monomers N-glycans and 2chainA + 1chainB + 1chainC O-glycans) was
derived according to available glycoanalytic data (Tables S1−
S3 for composition).11,31 We remark that the saccharides
originally solved in the cryo-EM structures have been generally
retained and utilized as a basic scaffold, when possible, to build
the full glycan structure using CHARMM-GUI (details in the
Materials and Methods section in the SI).37−39 The full-length
structures were embedded into an equilibrated all-atom
membrane bilayer with a composition mimicking the
endoplasmic reticulum-Golgi intermediate compartment
(ERGIC, Table S4 for composition), where the virus buds.
The membrane was generated through CHARMM-GUI.40
Subsequently, explicit water molecules and ions were added,
affording two final systems each tallying ∼1.7 million atoms.
Using CHARMM36 all-atom additive force fields41,42 and
NAMD 2.14,43 multiple replicas of all-atom MD simulations of
the Open (6x) and Closed (3x) systems were run on the NSF
Frontera computing system at the Texas Advanced Computing
Center (TACC), achieving benchmarks of ∼60 ns/day on 256
nodes for cumulative extensive sampling of ∼4.2 and ∼1.7 μs,
respectively (Table S5, Movie S1). Note that, since RBD-A
within Open is captured in a metastable state,32 Open was
simulated for a longer time than Closed. Visual inspection of
trajectories was performed with VMD44 that, together with
MDtraj,45 was also used for analyses.
Topological domain-specific root-mean-square-deviation
(RMSD) relative to the starting structures was calculated to
examine the structural stability along the simulations (Figures
S2 and S3). Overall, the two systems showed structural
convergence of the extracellular topological domains (head and
stalk) within ∼400 ns. No significant difference was observed
in the RMSD values of the stalk between the systems (Figure
S3). Besides displaying a replica-specific convergence of
RMSD values, the triple-stranded coiled-coil structural motif
of the stalk persists throughout the simulations (Movie S1).
Notably, as a result of secondary structure prediction (see
Materials and Methods in the SI), the stalk model includes two
loops that break the α-helix within each strand (Figure 1B).
Along with linked N-glycans, these loops confer critical
dynamic properties to the stalk, allowing it to bend to
accommodate the head’s wiggling motions while remaining
anchored to the membrane (Movie S1). The RMSD values of
the CT domain show extremely large deviations and a mixed
range of dynamic behaviors across replicas (Figure S3). While
the first section of CT remains anchored to the inner-leaflet of
the lipid bilayer through the palmitoylated cysteines, the rest is
highly flexible and solvent exposed.
The root-mean-square-fluctuation (RMSF) values of the
glycans were measured to determine their average flexibility
around their mean position across the trajectories of all replicas
(Figure S4). These values indicate a diverse range of mobility
for specific sites, which is mostly dependent on solvent
exposure, branching, and sequence. Complex-type N-glycans
located on the NTD exhibit larger RMSF values than
oligomannose-type and other N-glycans populating the head,
including the ones in the RBD at sites N331 and N343.
Interestingly, the O-glycans linked in the immediate vicinity of
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the RBD, namely at T323 and S325, show the lowest RMSF
values. This is mostly attributable to their small size; however,
their position may be critical for modulating RBD conforma-
tional changes, although we note that both positions are not
consistently occupied. Finally, the large tetrantennary N-
glycans in the stalk region at N1173 and N1194, modeled
consistently with experimental data,11 show the most extensive
fluctuations, suggesting their good shielding potential.
The stability of the membrane bilayer was also monitored by
tracking the time evolution of a series of structural properties,
including area per lipid, membrane thickness, order parame-
ters, and phospholipid tilt angles. Equilibrium area per lipid
and membrane thickness plots are shown in Figure S5. These
results are in agreement with known POPC and previously
reported binary POPC + X trends, where X is any other lipid
added to the mix.46−52
N-Glycans at N165 and N234 Modulate the RBD
Conformational Dynamics. SARS-CoV and SARS-CoV-2 S
glycoproteins share 76% sequence identity,12 and 18 out of 22
N-glycosylation sites found on SARS-CoV-2 are conserved
from SARS-CoV. Based on the analysis of our simulations of
the full-length model of the SARS-CoV-2 S protein, we
identified two N-glycans linked to N165 and N234 in the
NTD, which, given their strategic position and structure, we
hypothesized may play a role in the RBD conformational
dynamics. Our simulations show that in Closed, the N-glycan
at N234 within NTD-B, modeled as Man9 in agreement with
glycoanalytic data,11 is pointing away from the core of the S
protein and is directed toward the solvent (Figure 2A); in
contrast, in Open, where the RBD of chain A is “up,” the same
Man9 linked to N234 of NTD-B is directed inward, inserting
itself into the large volume left vacant by the opening of RBD-
A (Figures 2B and 2C). Because the glycans were built by
structural alignment on the linked GlcNAc (or chitobiose)
residues, wherever available, the relative position of the existing
GlcNAc or chitobiose may affect the orientation of the entire
N-glycan. Indeed, the N-glycan core is quite rigid.53 To further
assess the possible impact of the force fields and/or of the
starting cryo-EM structure on the simulations described here,
we performed an additional set of simulations of the open
SARS-CoV-2 S protein’s head using AMBER ff14SB/
GLYCAM06j-1 force fields54,55 and an alternative initial
cryo-EM structure (PDB ID: 6VYB),56 which presents the
GlcNAc linked to N234 in a slightly different orientation.
These simulations, detailed in Section 2 of the SI, show that
the Man9 glycan at N234 progressively inserts itself to reach
the apical core of the trimer through interactions with the
surface of the closed RBD domain located across from it
(Movie S2), adopting a structural arrangement similar to the
one described in Figure 2B. The highly conserved N-glycan at
N165 also inserts itself between NTD-B and RBD-A, either
making extensive interactions with RBD-A or occupying the
volume left vacant following its opening (Figure 2C). This was
also observed in the additional simulations described in
Section 2 of the SI.
Figure 2. N234A and N165A mutations show increased instability of RBD-A in the “up” state. (A, B) Top view of the S protein as in the Closed
(A) and Open (B) systems. Protein is represented with cartoons, colored in cyan, red, and gray for chains A, B, and C, respectively. Oligomannose
N-glycans at position N234 from all chains are shown in Van der Waals representation, where GlcNAc and mannose are colored in blue and green,
respectively. In Closed (A), all the N-glycans at N234 are tangential to a hypothetical circle going through N234. In Open (B), the N-glycan at
N234 of NTD-B moves inward, filling in the vacancy under RBD-A in the “up” conformation. (C) Side view of the S protein (surface
representation) in Open, where the RBD of chain A (RBD-A, cyan) is stabilized by N-glycans at N165 and N234 in the “up” conformation. The
same color scheme as panels A and B is applied. (D) PCA plot showing PC1 vs PC2 of RBD-A (residues 330−530) in Closed (blue), Open (teal),
and Mutant (magenta). The amount (%) of variance accounted by each PC is shown between parentheses.
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In light of these observations, an additional third system,
“Mutant”, was generated from Open by introducing N165A
and N234A mutations, which led to glycan deletions at the
respective sites. Mutant was then simulated through all-atom
MD for six replicas totaling ∼4.2 μs (Table S5). To determine
the structural consequences of removing these two glycans, we
compared the conformational landscape of the RBD in Open,
Mutant, and Closed systems using principal component
analysis (PCA). Scatterplot projections of RBD-A dynamics
onto the first two eigenvectors (PC1 vs PC2), i.e., the two
motions with the largest variance in the trajectories (65% and
15%, respectively), clearly indicate that the RBD-A in Mutant
explores a larger conformational space than in Open, which in
turn is considerably larger than in Closed (Figure 2D).
Although the difference between Open and Closed is
immediately explained by the RBD-A state (“up/down”), the
PCA landscape pinpoints a more stable RBD “up” con-
formation in the presence of N165 and N234, thus suggesting
a structural role for the respective N-linked glycans (Movie
S3). Detailed analysis of the PCA space explored by RBD-A,
including the comparison between Open and Mutant only and
the per-replica contribution in all systems, is presented in
Figures S6 and S7. Analysis of RMSD along the trajectory
further highlights the instability of RBD-A in Mutant (Figure
S2). This behavior is confirmed even in the case of a single
point mutation (N234A), as revealed by the additional
independent simulations of the spike head described in Section
2 of SI. In contrast to RBD-A, RBD-B and RBD-C are in the
“down” conformation in all three systems, showing mostly
stable overlapping PCA distributions (Figure S7).
To obtain further insights into the RBD-A dynamic behavior
and examine the differences in the explored conformational
spaces revealed by PCA, we monitored the variations along the
dynamics of two angles describing RBD-A fluctuations,
hereafter referred to as the “lateral-angle” and “axial-angle”.
The lateral-angle reports an in-plane motion of the RBD along
a hypothetical circle centered on the central helices of the spike
(Figure 3A). This angle is described by three points
corresponding to the (i) the center of mass (COM) of
RBD-A core β-sheets at frame 0, (ii - vertex) the COM of the
top section of the CH, and (iii) the COM of RBD-A core β-
sheets at each frame along the trajectory. The axial-angle
identifies a tilting motion of the RBD either away from or
toward the CH of the spike (Figure 3B). This angle is defined
by three points corresponding to (i) the COM of RBD-A core
β-sheets, (ii - vertex) the COM of the CH, and (iii) the COM
of the top section of the CH. The distributions of the lateral-
and axial-angle fluctuations along the trajectories of each
system are shown in Figures 3C and 3D. Angle variations were
calculated with respect to their initial values at frame 0 of the
trajectories. Full details on angle definitions and calculations
are outlined in the Materials and Methods section in the SI.
In agreement with the dynamic behavior revealed by PCA
(Figure 2D), the RBD-A lateral-angle displays a well-defined
Figure 3. RBD-A lateral- and axial-angle fluctuations. (A, B) RBD-A lateral-angle (A) and axial-angle (B), where chains A, B, and C of the spike are
represented as cartoons colored in cyan, red, and gray, respectively. Positive and negative variations with respect to the initial frame (0) are
indicated with the “+” and “−” symbols, respectively. N-/O-Glycans and some structural domains of the spike are omitted for clarity. (C, D)
Distributions of RBD-A lateral-angle (C) and axial-angle (D) fluctuations along the trajectories (across all replicas) in Closed (blue), Open (teal),
and Mutant (magenta). Angle variations were calculated with respect to their value at frame 0. Frequencies have been normalized within the
respective data sets.
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single distribution centered on zero in Open, whereas it
exhibits a bimodal population in Mutant (Figure 3C). This
analysis shows that the presence of the NTD-B N-glycans at
N165 and N234 is crucial to stabilize the RBD-A “up”
conformation, preventing it from undergoing disordered
motions. Interestingly, the axial-angle analysis results display
a similar behavior of RBD-A in Open and Mutant, showing a
long tail distribution in both systems (Figure 3D). However,
Mutant exhibits a significant negative trend, whereas Open
shows a positive trend. This suggests that the N-glycans at
N165 and N234 may play a critical role not only in stabilizing
the RBD “up” conformation but also in modulating RBD
opening and closing, thus potentially affecting binding to
ACE2. Indeed, whereas the RBD in the “down” state overlies
on the CH of the spike trimer, thus not being accessible to
ACE2, when it transitions to the “up” state, it detaches from
the central axis, protruding into the solvent and becoming
available for binding.
To confirm the hypothesis unveiled by our simulations, we
sought to experimentally assess the effects of N165 and N234
deletions on the RBD state. To quantify RBD accessibility in
solution, we used biolayer interferometry to measure ACE2
binding to the S protein containing either N165A or N234A
substitutions. As a result, ablation of these N-linked sites
reduces the binding responses for N165A and N234A mutants
to ∼90% and ∼60% (p = 0.0051 and p = 0.0002, Student’s t
test) as high as the parent S-2P variant, respectively (Figure 4).
We remark that the S-2P variant of the S protein bears two
consecutive proline substitutions within the S2 subunit that are
introduced to stabilize the prefusion conformation.32 Im-
portantly, a negative control spike (HexaPro), engineered with
S383C/D985C mutations to lock all three RBDs in the closed
state through a disulfide bond,57 shows no binding to ACE2.
These experiments corroborate the hypothesis that N165 and
N234 glycans stabilize the RBD “up” conformation, therefore
facilitating binding to ACE2, with the N234 glycan playing a
larger role than N165.
To characterize how the N-glycans at N165 and N234
stabilize the RBD in the “up” state, we examined their
interaction with the S protein through hydrogen bond analysis.
Man9 linked to N234 on NTD-B deeply extends into the large
pocket created by the opening of the RBD-A (Figure 5C).
Specifically, it largely interconnects with the lower part of
RBD-A (H519 in particular), propping it up from underneath,
makes stable hydrogen bonds with D198 of NTD-B, and
interacts as deep as R983, D985, and E988 located within the
CH of chain B (Movie S3). All of these hydrogen bonds are
stable for more than 40% of the comprehensive 4.2 μs
trajectory of the Open system, with the majority of hydrogen
bonds formed with the CH of chain B and RBD-A (see Figure
5A). The N-glycan at N165 is more exposed to the solvent
with respect to the Man9 glycan at N234; nevertheless, it
extensively engages in interactions with the “up” conformation
of RBD-A (∼90% frequency) with a variable hydrogen
bonding pattern across simulation replicas (Figures 5B and
5D, Figure S8, Movie S3). The per-replica hydrogen bond
networks observed for the N-glycans at N234 and N165 are
shown in Figure S9.
Altogether, the heterogeneous conformational dynamics
disclosed by PCA and angle analysis, together with the
reduced ACE2-binding responses revealed by biolayer
interferometry experiments, show that the conformational
plasticity of the RBD is affected by the absence of N-glycans at
N165 and N234. Notably, two flexible linker loops, connecting
the RBD with the receptor-binding C-terminal domain 2
(CTD2) located underneath, prime the RBD to undergo large
conformational rearrangements, such as the ACE2-induced
hinge motion.58 In this scenario, the subtle “up/down”
equilibrium of the RBD can be dramatically altered by
introducing single point mutations within the RBD or nearby
regions57 or also by varying pH conditions.59 Our work reveals
that, similarly to MERS spike’s RBD,60 the SARS-CoV-2
spike’s RBD “up” state is metastable within its conformational
ensemble. We find that the RBD necessitates two N-glycans
located on the adjacent NTD, namely N165 and N234, to
“load-and-lock” the “up” conformation and to successfully bind
to ACE2 receptors. Although our simulations do not show a
full “up-to-down” transition of the RBD, the investigated
glycan-deleting mutations cause the RBD in the “up” state to
experience a larger conformational freedom and to undergo
wider tilting motions. As a consequence, this conformational
instability might increase the vulnerability of the virus, as
cryptic epitopes located on the RBD might become more
exposed to antibody recognition,61,62 and, most likely, might
decrease the virus infectivity as a result of a possible
conformational shift of the RBD toward the closed state.
Here, through biolayer interferometry experiments, we show
that binding to ACE2 is remarkably reduced for the N234A
mutant and slightly impaired for the N165A variant, whereas it
is completely abolished in the case of an engineered S protein
with all three RBDs locked in the “down” state. As such, these
experiments, confirming the computational predictions,
advocate for a conformational shift of the RBD population
toward the “down” state as a result of the depletion of N234
and N165 glycans. This is consistent with the dynamics of the
Man9 glycan linked to N234, which we observe crawling
toward the apical portion of the spike’s central axis, filling in
the space left vacant by the RBD in the “up” conformation, and
engaging in persistent interactions both with the same RBD
“up” and the CH. Hence, it is not surprising that this glycan
plays a larger role in stabilizing the RBD “up” than the glycan
at N165, which is more solvent exposed and whose interaction
pattern is less defined. However, we show that N165 steadily
interacts with the RBD, therefore also contributing to loading
and locking the “up” state, although to a lesser extent.
The SARS-CoV-2 spike’s marked sensitivity to mutations
affecting its structural dynamics represents an opportunity for
Figure 4. N234A and N165A mutations of the spike reduce binding
to ACE2. (A) Representative biolayer interferometry sensorgrams
showing binding of ACE2 to spike variants. (B) Binding responses for
biolayer interferometry measurements of ACE2 binding to spike
variants. Data are shown as mean ± standard deviation from three
independent experiments for each variant. Asterisks represent
statistical significance (Student’s t test; *0.01 < p < 0.05, **0.001 >
p > 0.01, ***0.0001 < p < 0.001).
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vaccine design,32,63 especially when it entails the alteration of
the RBD “up/down” equilibrium.57 In this context, our
findings pinpoint the possibility of controlling the RBD
conformational plasticity by introducing N165A and N234A
mutations. These N-linked sites−N234 in particular−are
essential for locking the RBD in the open state, thus
contributing to priming the SARS-CoV-2 virus to recognize
ACE2 receptors and invade host cells. Excising these glycans
might result in less infectious, or “weakened”, viruses bearing S
proteins with predominantly “down” RBDs. This scenario
would not prevent a humoral immune response targeting the
upper side of the RBD,64 including the RBM, since the RBDs
would still be able to transition to the “up” state, although to a
lesser extent. Instead, it might stimulate a larger production of
antibodies recognizing other known epitopes located either on
the core of the RBD,65,66 or on the NTD,67 or other S2
regions,68 which might be engaged even in the closed state.
Glycan Shield of the Full-Length SARS-CoV-2 S
Protein. In the context of vaccine design, it is critical to
consider all the strategies developed by viruses to evade the
host immune response. Within this framework, many viruses
use a glycan shield to mask the immunogenic epitopes targeted
by neutralizing antibodies.11,15 The SARS-CoV-2 S protein
glycosylation is extensive and capable of thwarting the host
humoral recognition.11,15,69 In addition to the spike head and
RBD,61,70 another possible attractive target for antibodies is the
stalk, as also shown in influenza virus studies.71 Whereas 19 N-
glycans essentially camouflage the spike head region, only 3 N-
glycosylation sites (N1158, N1174, and N1194) are present on
the stalk. Exploiting the extensive sampling derived from all-
atom simulations of our full-length model of the SARS-CoV-2
S glycoprotein, we provide an unprecedented end-to-end
overview of the spike’s glycan shield (Figure 6). In Figure 6A,
each blue bushlike structure represents an ensemble of equally
interspersed conformations of a single glycan sampled along a
1 μs trajectory for a total of 300 superimposed poses.
Considering the different time scales of the dynamics of
these N-glycans (nanoseconds), relative to the antibody/spike
binding process (microseconds to milliseconds), this repre-
sentation provides a realistic view of the shielding that
molecules targeting the spike might encounter before binding.
To quantify this shielding effect, we calculated the S protein’s
accessible surface area (ASA) that is covered by glycans on
both the head and stalk regions of the Open system. We also
screened a wide range of probe radii, from 1.4 to 15 Å, to
measure the effectiveness of the shield with respect to
molecules of different sizes. A value of 1.4 Å is commonly
set to approximate the radius of a water molecule, whereas
larger radii can be used to describe larger moieties, ranging
from small molecules at 2−5 Å to larger peptide- and antibody-
sized molecules at 10−15 Å.69,72
Our results indicate that the head is overall less shielded by
the glycans than the stalk at all probe radii (Figures 6B and
6C). Interestingly, the stalk is almost completely inaccessible
to large molecules such as antibodies, with glycan coverage
equal to 90% of the protein accessible area for a 15-Å-radius
probe. On the contrary, the head represents an easier target as
its glycan camouflaging is insufficient (62%) to cover its larger
surface area, which includes one RBD in the “up”
conformation. When smaller probes are screened (1.4−3 Å
radius), the stalk and the head are similarly shielded at an
average of 26% and 20%, respectively, suggesting that small
molecules can equally penetrate either area. ASA average and
standard deviation values for the head and stalk in Open are
provided in Tables S6 and S7, respectively. Overall, taking
glycosylation into account, the stalk appears as a potentially
Figure 5. Hydrogen bond interactions of N-glycans at N234 and N165. The main hydrogen bond interactions of N-glycans at N234 (A) and N165
(B) within the Open system are shown as occupancy across all replicas (% frames). (C) A snapshot capturing Man9 glycan at N234 (licorice
representation) within NTD-B establishing multiple hydrogen bonds with S protein residues (thicker licorice representation) belonging to RBD-A
(cyan surface), NTD-B (red surface), CH-B (red cartoons), and CH-C (gray cartoons). GlcNAc and mannose carbons are colored in blue and
green, respectively. (D) Molecular representation of Man5 glycan at N165 within NTD-B interacting with RBD-A. Multiple (1000) equally
interspersed configurations (selected across all replicas) of the glycan at N165 from NTD-B are simultaneously shown. The glycan is represented as
colored licorices (GlcNAc in blue, mannose in green), whereas RBD-A and NTD-B are represented as cyan and red surfaces, respectively.
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more difficult therapeutic target than the head, despite being a
highly conserved domain among betacoronaviruses. Its smaller
surface is well-protected by large sialylated and fucosylated
tetrantennary glycans, which are found to be almost 100%
effective in shielding large molecules. Interestingly, glycans at
N1174 and N1198 have been found to always be
tetrantennary, 100% fucosylated (N1174 and N1198), and
100% sialylated (N1198).11,15 However, small drugs might still
interfere with the fusion process by binding to the HR2
domain of the stalk. In contrast, the head shows a higher
vulnerability, which can be harnessed for therapeutics develop-
ment.
Glycan Shield of the Receptor Binding Domain. As
discussed in the previous section, the glycan shield plays a
critical role in hiding the S protein surface from molecular
recognition. However, to effectively function, the spike needs
to recognize and bind to ACE2 receptors as the primary host
cell infection route. For this reason, the RBM must become
fully exposed and accessible.73 In this scenario, the glycan
shield works in concert with a large conformational change that
allows the RBD to emerge above the N-glycan coverage. Here,
we quantify the ASA of the RBM within RBD-A,
corresponding to the RBD/ACE2-interacting region (residues
400−508), at various probe radii in both the Open and Closed
systems (Figures 7A and 7D, full data in Tables S8−S10). As
expected, the ASA plots show a significant difference between
the “down” (Closed) and “up” (Open) RBD conformations,
with the RBM area covered by glycans being remarkably larger
in the former. When RBD-A is in the “up” conformation, its
RBM shows an average (across all radii) of only ∼9% surface
area covered by glycans, compared with ∼35% in the Closed
system (Figures 7A and 7D). This difference is further
amplified when considering a larger probe radius of 15 Å, with
a maximum of 11% and 46% for Open and Closed,
respectively. Interestingly, for smaller probes (1.4−3 Å) the
shielding becomes weak in both systems, with an average of 6%
and 16% for Open and Closed, respectively.
Note that the RBD region that does not directly interact
with ACE2 remains shielded by the glycans in both “up” and
“down” conformations (Figure S10). This region is equally
protected regardless of the RBD conformation mostly owing to
the presence of N-glycans bound to the RBD itself at N331
and N343 and to the N-glycans at N165 and N234 (Figure
S11). Ultimately, this analysis shows that the RBM is always
accessible when RBD is “up”, whereas it is very well-
camouflaged when RBD is “down” (Figure 7). This suggests
Figure 6. Glycan shield of the SARS-CoV-2 S protein. (A) Molecular representation of the Open system. Glycans at several frames (namely, 300
frames, one every 30 ns from one replica) are represented with blue lines, whereas the protein is shown with cartoons and highlighted with a cyan
transparent surface. Color code used for lipid tails (licorice representation): POPC (pink), POPE (purple), POPI (orange), POPS (red),
cholesterol (yellow). P atoms of the lipid heads are shown with green spheres. Cholesterol’s O3 atoms are shown with yellow spheres. (B, C)
Accessible surface area of the head (B) and stalk (C) and the area shielded by glycans at multiple probe radii from 1.4 (water molecule) to 15 Å
(antibody-sized molecule). The values have been calculated and averaged across all replicas of Open and are reported with standard deviation. The
area shielded by the glycans is presented in blue (rounded % values are reported), whereas the gray line represents the accessible area of the protein
in the absence of glycans. Highlighted in cyan is the area that remains accessible in the presence of glycans, which is also graphically depicted on the
structure in the panels located above the plots.
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that the glycan shield of this critical domain is effectively paired
with its “down-to-up” conformational change, allowing the
RBM to transiently emerge from the glycan shield and bind to
ACE2 receptors. Furthermore, while antibody targeting the
RBD might be ineffective when the RBD is “down”, small
molecules could more easily circumvent the glycan coverage.
This is in agreement with structural data reporting the “up”
conformation as a requirement for RBD neutralization by host
antibodies.74 In this respect, several SARS-CoV-2 antibodies
targeting the S protein have been identified (Table
S11).61,62,64−68,75−79 The majority of these antibodies
recognizes epitopes on the RBD, while only a few have been
shown to address other antigenic regions within the NTD and
CD (Figure S12). Among the RBD antibodies, B38 interacts
with the RBM at the RBD/ACE2 interface,64 whereas S309
and CR3022 target the side/bottom part of the RBD.61,62,65 In
addition, 4A8 and 1A9 have been found to engage with the
NTD and CD, respectively.67,68 Analysis of the glycan shield
effective on these epitopes is provided in Section 3 of the SI.
■ CONCLUSIONS
Our work presents multiple microsecond-long, all-atom,
explicitly solvated MD simulations of the full-length model
of the glycosylated SARS-CoV-2 S protein embedded in a viral
membrane. We show how the time-averaged glycan shield
covers a vast amount of the S protein surface area and how it
changes depending on the conformational state of the protein
between open and closed states. Interestingly, our simulated
models reveal a role−beyond shielding−for N-glycans at
positions N165 and N234 as modulators of the RBD
Figure 7. Glycan shield of the RBD ACE2-interacting region. The accessible surface area of the RBM-A and the area shielded by neighboring
glycans in the Closed (A) and Open (D) systems are plotted at multiple probe radii from 1.4 (water molecule) to 15 Å (antibody-sized molecule).
The values have been averaged across replicas and are reported with standard deviation. In blue is the area of the RBM-A covered by the glycans
(rounded % values are reported), whereas the gray line is the accessible area in the absence of glycans. Highlighted in cyan is the RBM-A area that
remains accessible in the presence of glycans, which is also graphically depicted on the structure in the panels located below the plots. (B−F)
Molecular representation of Closed and Open systems from top (B and E, respectively) and side (C and F, respectively) views. Glycans (blue lines)
are represented at several frames equally interspersed along the trajectories (300 frames along 0.55 ns for Closed and 1.0 μs for Open), while the
protein is shown with colored cartoons and a transparent surface (cyan, red, and gray for chains A, B, and C, respectively). Importantly, in panels E
and F, RBD within chain A (cyan) is in the “up” conformation and emerges from the glycan shield.
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conformational plasticity. Simulations of the N165A/N234A
and of N234A mutants of the S protein highlight their critical
structural role in stabilizing the RBD “up” conformation. To
confirm our simulation results, biolayer interferometry experi-
ments conducted on N165A and N234A variants show a
reduced ACE2 binding when these glycans are removed,
revealing an RBD conformational shift toward the “down”
state, with a larger effect for N234A. Overall, our work sheds
new light on the full structure of this critical target and points
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Gibbs, J. S.; Casalino, L.; Amaro, R. E.; Hensley, S. E.; Nelson, M. I.;
Yewdell, J. W. Human Influenza a Virus Hemagglutinin Glycan
Evolution Follows a Temporal Pattern to a Glycan Limit. mBio 2019,
DOI: 10.1128/mBio.00204-19.
(29) Behrens, A. J.; Crispin, M. Structural Principles Controlling
HIV Envelope Glycosylation. Curr. Opin. Struct. Biol. 2017, 44, 125−
133.
(30) Geijtenbeek, T. B. H.; Kwon, D. S.; Torensma, R.; Van Vliet, S.
J.; Van Duijnhoven, G. C. F.; Middel, J.; Cornelissen, I. L. M. H. A.;
Nottet, H. S. L. M.; KewalRamani, V. N.; Littman, D. R.; Figdor, C.
G.; Van Kooyk, Y. DC-SIGN, a Dendritic Cell-Specific HIV-1-
Binding Protein That Enhances Trans-Infection of T Cells. Cell 2000,
100 (5), 587−597.
(31) Shajahan, A.; Supekar, N. T.; Gleinich, A. S.; Azadi, P.
Deducing the N-and O-Glycosylation Profile of the Spike Protein of
Novel Coronavirus SARS-CoV-2. Glycobiology 2020, cwaa042.
(32) Wrapp, D.; Wang, N.; Corbett, K. S.; Goldsmith, J. A.; Hsieh,
C.-L.; Abiona, O.; Graham, B. S.; McLellan, J. S. Cryo-EM Structure
ACS Central Science http://pubs.acs.org/journal/acscii Research Article
https://dx.doi.org/10.1021/acscentsci.0c01056
ACS Cent. Sci. 2020, 6, 1722−1734
1732
of the 2019-NCoV Spike in the Prefusion Conformation. Science
2020, 367 (March), 1260−1263.
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